Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)
rovunaptabin（又名 BC007）对 COVID 后遗症患者疲劳和生活质量的安全性、耐受性和临床疗效 (reCOVer)：一项前瞻性、探索性、安慰剂对照、双盲、随机 IIa 期临床试验 (RCT)
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103358
Hohberger, Bettina; Ganslmayer, Marion; Harrer, Thomas; Kruse, Friedrich; Maas, Stefanie; Borst, Tobias; Heimke-Brinck, Ralph; Stog, Andreas; Knauer, Thomas; Rühl, Eva; Zeisberg, Victoria; Skornia, Adam; Bartsch, Alexander; Ströbel, Armin; Wytopil, Monika; Merkel, Caroline; Hofmann, Sophia; Schmidt, Katja G; Lakatos, Petra; Schottenhamml, Julia; Herrmann, Martin; Mardin, Christian; Rech, Jürgen
